N-(2-[7-(3-hydroxypropoxy)-naphthalen-1-yl]ethyl)acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-[7-(3-hydroxypropoxy)-naphthalen-1-yl]ethyl)acetamide
• 英文别名: N-{2-[7-(3-hydroxypropyloxy)naphth-1-yl]ethyl}acetamide；N-[2-[7-(3-hydroxypropoxy)naphthalen-1-yl]ethyl]acetamide
• 化学式: C₁₇H₂₁NO₃
• 分子量: 287.359
• InChiKey: XWUBJQZPAAFOQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-[7-(3-hydroxypropoxy)-naphthalen-1-yl]ethyl)acetamide 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 以15%的产率得到N-(2-[7-(3-fluoropropoxy)-naphthalen-1-yl]ethyl)acetamide
  参考文献：
  名称：

  Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I)

  摘要：

  As part of our ongoing interest in developing new melatoninergic ligands bearing the same pharmacological profile as agomelatine, we focused our attention on this compound as a lead. Several chemical modifications have been performed on positions C-3 and 8 of the naphthalene ring determined as primary targets for the agomelatine metabolism. Herein we report the modulation of the positions C-3 and 7 in addition of the amide side chain because of this later prominent role in the affinity profile of such ligands. Synthesized compounds were then biologically evaluated at human cloned melatoninergic and serotoninergic receptors and showed different binding affinity and intrinsic activity profiles. Compounds bearing fluoroacetamide group (compounds 4 and 5) showed a high melatoninergic binding affinity particularly towards MT1 receptor subtype. Thus, the fluoroacetamide 4 exhibited a good melatoninergic (mT(1)/MT2) binding affinity (70 pm) higher than the lead. Moreover, other compounds (10a, 10e, 16, 17 and 18) issued from these modulations behaved as MT1 and MT2 agonists and exhibited a sub-nanomolar binding affinity towards these receptors. However, only compounds 10e, 17 and 18 showed a sub-nanomolar binding affinity at 5-HT2C higher than the agomelatine. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.01.027
• 作为产物：
  描述：

  阿戈美拉汀 在 四丁基溴化铵 、 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 7.5h， 生成 N-(2-[7-(3-hydroxypropoxy)-naphthalen-1-yl]ethyl)acetamide
  参考文献：
  名称：

  Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I)

  摘要：

  As part of our ongoing interest in developing new melatoninergic ligands bearing the same pharmacological profile as agomelatine, we focused our attention on this compound as a lead. Several chemical modifications have been performed on positions C-3 and 8 of the naphthalene ring determined as primary targets for the agomelatine metabolism. Herein we report the modulation of the positions C-3 and 7 in addition of the amide side chain because of this later prominent role in the affinity profile of such ligands. Synthesized compounds were then biologically evaluated at human cloned melatoninergic and serotoninergic receptors and showed different binding affinity and intrinsic activity profiles. Compounds bearing fluoroacetamide group (compounds 4 and 5) showed a high melatoninergic binding affinity particularly towards MT1 receptor subtype. Thus, the fluoroacetamide 4 exhibited a good melatoninergic (mT(1)/MT2) binding affinity (70 pm) higher than the lead. Moreover, other compounds (10a, 10e, 16, 17 and 18) issued from these modulations behaved as MT1 and MT2 agonists and exhibited a sub-nanomolar binding affinity towards these receptors. However, only compounds 10e, 17 and 18 showed a sub-nanomolar binding affinity at 5-HT2C higher than the agomelatine. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.01.027

文献信息

• Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same
  申请人：——

  公开号：US20040014969A1

  公开（公告）日：2004-01-22

  The invention relates to compound of formula (I): 1 wherein: B represents hydrogen, COOR, CONRR′, or (C 1 -C 6 )alkyl substituted by COOR, CONRR′, or OR, G 1 represents —X′—(CH 2 ) n —X—(CH 2 ) m —X″—chain wherein X, X′, X″, n and m are as defined in the description, Cy represents a grouping of formula (II) or (III): 2 G 2 represents alkylene chain as defined in the description, and A represents NRCOR′, NRCSR′, CONRR′, CSNRR′, NRCONR′R″, or NRCSNR′R″, and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

  本发明涉及式(I)的化合物：1其中：B代表氢、COOR、CONRR′或被COOR、CONRR′或OR取代的(C1-C6)烷基；G1代表—X′—(CH2)n—X—(CH2)m—X″—链，其中X、X′、X″、n和m如描述中所定义；Cy代表式(II)或(III)的基团：2G2代表如描述中所定义的烷基链；A代表NRCOR′、NRCSR′、CONRR′、CSNRR′、NRCONR′R″或NRCSNR′R″；以及含有这些化合物的药物制剂，用于治疗或预防褪黑激素失调症。
• Substituted dimeric compounds
  申请人：——

  公开号：US20020035114A1

  公开（公告）日：2002-03-21

  The invention relates to compounds of formula (I): A—G 1 —Cy—G 2 —Cy—G 3 —B  (I) wherein: A represents NR 1 C(Q)R 2 , C(Q)NR 2 R 3 or NR 1 C(Q)NR 2 R 3 , B represents NR 1 C(Q)R 2 , C(Q)NR 2 R 3 , NR 1 C(Q)NR 2 R 3 , C(Q)OR 1 , NR 1 C(Q)OR 2 or NR 2 R 3 , G 1 and G 3 represent an optionally substituted alkylene chain, Cy represents a ring structure 1 G 2 represents a chain and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.

  本发明涉及式(I)的化合物：A-G1-Cy-G2-Cy-G3-B  (I)，其中：A代表NR1C(Q)R2，C(Q)NR2R3或NR1C(Q)NR2R3，B代表NR1C(Q)R2，C(Q)NR2R3，NR1C(Q)NR2R3，C(Q)OR1，NR1C(Q)OR2或NR2R3，G1和G3代表可选取代的烷基链，Cy代表环结构，G2代表链，以及含有这些化合物的药物，其在治疗或预防褪黑激素失调方面有用。
• Substituted biphenyl compounds
  申请人：Descamps-Francois Carole

  公开号：US20070123529A1

  公开（公告）日：2007-05-31

  The invention relates to compound of formula (I) wherein: B represents hydrogen, COOR, CONRR′, or (C 1 -C 6 )alkyl substituted by COOR, CONRR′, or OR, G 1 represents —X′—(CH 2 ) n —X—(CH 2 ) m —X″— chain wherein X, X′, X″, n and m are as defined in the description, Cy represents a grouping of formula (II) or (III): G 2 represents alkylene chain as defined in the description, and A represents NRCOR′, NRCSR′, CONRR′, CSNRR′, NRCONR′R″, or NRCSNR′R″. and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

  本发明涉及式（I）的化合物： 其中： B代表氢、COOR、CONRR′或被COOR、CONRR′或OR取代的（C1-C6）烷基， G1代表式（II）或（III）的基团： Cy代表式（II）或（III）的基团： G2代表如说明书中所定义的烷基链， A代表NRCOR′、NRCSR′、CONRR′、CSNRR′、NRCONR′R″或NRCSNR′R″。 本发明还涉及含有上述化合物的药物制剂，其在治疗或预防褪黑素能紊乱方面具有有用性。
• Dérivés carboxamides dimériques substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：ADIR ET COMPAGNIE

  公开号：EP1057826A1

  公开（公告）日：2000-12-06

  L'invention concerne les composés de formule (I) :         A-G1-Cy-G2-Cy'-G3-B     (I) dans laquelle : A représente un groupement NR1C(Q)R2, C(Q)NR2R3 ou NR1C(Q)NR2R3, B représente un groupement NR1C(Q)R2, NR1C(Q)NR2R3, C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2, NR2R1, G1, G3 représentent une chaîne alkylène éventuellement substituée, Cy et Cy', différents, représentent une structure cyclique ou G2 représente une chaîne Médicaments

  本发明涉及式 (I) 化合物： A-G1-Cy-G2-Cy'-G3-B (I) 其中： A 代表基团 NR1C(Q)R2、C(Q)NR2R3 或 NR1C(Q)NR2R3、 B 代表基团 NR1C(Q)R2、NR1C(Q)NR2R3、C(Q)NR2R3、C(Q)OR1、NR1C(Q)OR2、NR2R1、 G1、G3 代表任选取代的亚烷基链、 不同的 Cy 和 Cy'代表环状结构 或 G2 代表链 药品
• Nouveaux dérivés dimériques substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：LES LABORATOIRES SERVIER

  公开号：EP1038863B1

  公开（公告）日：2003-06-04